Combat Declining Immunization Rates with Sanofi and CSL Limited Influenza Vaccines - Health

Sanofi and CSL Limited Roll Out Influenza Vaccines for 2024/25 Season

Customers will start receiving shipments from July 10 with additional shipments through October to healthcare provider offices , pharmacies and other immunizers to support fall immunization campaigns . Sanofi annual higher - dose influenza ( flu ) vaccinations have been proven to help protect from flu and shown to better protect from serious complications of flu such as pneumonia and cardiac events when compared to standard dose vaccines in older adults.

Sanofi today started shipping its first influenza ( flu ) vaccines across the U.S. in preparation for the 2024/25 Flu season . Following this first shipment , additional shipments of the full Sanofi flu vaccine portfolio will continue through October to healthcare provider offices , pharmacies and other immunizers to support fall immunization campaigns . With over 125 years of heritage in helping protect global public health , Sanofi is a world leader in vaccines , helping to vaccinate more than 500 million people annually.

 Customers will start receiving shipments from July 10 with additional shipments through October to healthcare provider offices , pharmacies and other immunizers to support fall immunization campaigns.

According to Stefan Merlo , Vice President of Commercial Operations , North America , CSL Seqirus , pharmacies in the United States will soon offer updated flu shots . Mr. Merlo exclusively informed Precision Vaccinations News that as of July 9 , 2024 , CSL Seqirus was already shipping its differentiated Influenza vaccines for the 2024/25 Northern Hemisphere flu season . " This year , we 've transitioned to trivalent vaccine formulations , aligning with U.S. FDA guidelines . "

Pharmacies in the United States will soon offer updated flu shots.

Combat Declining Immunization Rates with Sanofi and CSL Limited Influenza Vaccines

All flu vaccines provided by Sanofi to the US market are trivalent , meaning they offer protection against the current three strains of influenza ( two influenza A strains and one influenza B strain ) . These strains were selected based on a collaborative review of influenza surveillance by the U.S. Food and Drug Administration ( FDA ) , World Health Organization ( WHO ) , the Centers for Disease Control and Prevention ( CDC ) , among other public health experts , as the strains most likely to cause illness in the upcoming flu season . Summit ( Precision Vaccinations News ) stated that the recent declines in flu vaccination rates pose a significant impact on public health.

 This unfortunate trend was seen across various and vulnerable age groups , with a 22 % drop among children aged six months to 18 years and a 14 % decrease in adults over 65 , a group that typically maintains stable immunization rates.

Sanofi and CSL Seqirus are actively working to combat the decline in immunization rates and enhance awareness of the importance of flu vaccination . Both companies are committed to providing a variety of influenza vaccine options to meet the unique needs of different age groups and ensure that all eligible individuals can safely receive their annual flu vaccination . With shipments already underway , both Sanofi and CSL Seqirus are confident in their ability to deliver a consistent supply of vaccines to increase immunization rates and reduce the burden of influenza on public health.